Leckie J, Yokota T
Genes (Basel). 2025; 16(2).
PMID: 40004514
PMC: 11855077.
DOI: 10.3390/genes16020185.
Jony M, Joshi A, Dash A, Shukla S
Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861150
PMC: 11768406.
DOI: 10.3390/ph18010087.
Senol H, Yildiz G, Polat A, Aydin A, Hiz A, Soylu A
Brain Behav. 2025; 15(1):e70221.
PMID: 39829133
PMC: 11743982.
DOI: 10.1002/brb3.70221.
Ramirez-Cortes F, Menova P
RSC Med Chem. 2024; 16(2):525-544.
PMID: 39628900
PMC: 11609720.
DOI: 10.1039/d4md00652f.
Tani H
Int J Mol Sci. 2024; 25(22).
PMID: 39596348
PMC: 11594839.
DOI: 10.3390/ijms252212284.
Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.
Khuu A, Verreault M, Colin P, Tran H, Idbaih A
Cells. 2024; 13(22).
PMID: 39594617
PMC: 11592788.
DOI: 10.3390/cells13221869.
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.
Ogieuhi I, Callender K, Odukudu G, Obi E, Muzofa K, Babalola A
High Blood Press Cardiovasc Prev. 2024; 32(1):33-47.
PMID: 39476283
DOI: 10.1007/s40292-024-00682-w.
Current status and trends in small nucleic acid drug development: Leading the future.
Miao Y, Fu C, Yu Z, Yu L, Tang Y, Wei M
Acta Pharm Sin B. 2024; 14(9):3802-3817.
PMID: 39309508
PMC: 11413693.
DOI: 10.1016/j.apsb.2024.05.008.
Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside.
Cakan E, Lara O, Szymanowska A, Bayraktar E, Chavez-Reyes A, Lopez-Berestein G
Cancers (Basel). 2024; 16(17).
PMID: 39272802
PMC: 11394571.
DOI: 10.3390/cancers16172940.
Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine.
Matsubayashi T, Yoshioka K, Lei Mon S, Katsuyama M, Jia C, Yamaguchi T
Mol Ther Nucleic Acids. 2024; 35(2):102161.
PMID: 38978695
PMC: 11229412.
DOI: 10.1016/j.omtn.2024.102161.
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Sang A, Zhuo S, Bochanis A, Manautou J, Bahal R, Zhong X
BioDrugs. 2024; 38(4):511-526.
PMID: 38914784
PMC: 11695194.
DOI: 10.1007/s40259-024-00665-2.
Circ_0007432 promotes non-small cell lung cancer progression and macrophage M2 polarization through SRSF1/KLF12 axis.
Mao S, Wu D, Cheng X, Wu J
iScience. 2024; 27(6):109861.
PMID: 38799570
PMC: 11126953.
DOI: 10.1016/j.isci.2024.109861.
Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S, Simoncelli G, Ricci C
Int J Mol Sci. 2024; 25(9).
PMID: 38732027
PMC: 11083842.
DOI: 10.3390/ijms25094809.
ASOptimizer: Optimizing antisense oligonucleotides through deep learning for IDO1 gene regulation.
Hwang G, Kwon M, Seo D, Kim D, Lee D, Lee K
Mol Ther Nucleic Acids. 2024; 35(2):102186.
PMID: 38706632
PMC: 11066473.
DOI: 10.1016/j.omtn.2024.102186.
Inhibition of survivin by 2'--methyl phosphorothioate-modified steric-blocking antisense oligonucleotides.
Li Y, Chen S, Rahimizadeh K, Zhang Z, Veedu R
RSC Adv. 2024; 14(19):13336-13341.
PMID: 38660533
PMC: 11040434.
DOI: 10.1039/d4ra01925c.
Functional roles of circular RNAs in lung injury.
Gao F, Chen D, Jiang Y, Han C, Lin B, Yang Z
Front Pharmacol. 2024; 15:1354806.
PMID: 38601461
PMC: 11004487.
DOI: 10.3389/fphar.2024.1354806.
Utility of oligonucleotide in upregulating circular RNA production in a cellular model.
Ni L, Yamada T, Nakatani K
Sci Rep. 2024; 14(1):8096.
PMID: 38582789
PMC: 10998836.
DOI: 10.1038/s41598-024-58663-x.
The Dawning of a New Enterprise: RNA Therapeutics for the Skin.
Kieser R, Khan S, Bejar N, Kiss D
J Dermatol Skin Sci. 2024; 5(1):4-13.
PMID: 38435714
PMC: 10907068.
DOI: 10.29245/2767-5092/2023/1.1168.
Tissue pharmacokinetics of antisense oligonucleotides.
Backstrom E, Bonetti A, Johnsson P, Ohlin S, Dahlen A, Andersson P
Mol Ther Nucleic Acids. 2024; 35(1):102133.
PMID: 38419941
PMC: 10899043.
DOI: 10.1016/j.omtn.2024.102133.
A comparative analysis of peptide-delivered antisense antibiotics using diverse nucleotide mimics.
Ghosh C, Popella L, Dhamodharan V, Jung J, Dietzsch J, Barquist L
RNA. 2024; 30(6):624-643.
PMID: 38413166
PMC: 11098465.
DOI: 10.1261/rna.079969.124.